MannKind Expands Afrezza Label with FDA Pediatric Approval
Event summary
- FDA approved Afrezza for children and adolescents aged 6+ with diabetes on May 29, 2026.
- MannKind to host conference call at 4:30 PM ET to discuss the approval.
- CEO Michael Castagna and SVP Kevin Kaiserman to present.
- Webcast available on MannKind’s investor relations page.
The big picture
The pediatric approval extends Afrezza’s market potential in a segment where insulin alternatives are limited. MannKind’s focus on drug-device combinations positions it uniquely in diabetes care, though execution risks remain in converting regulatory wins into commercial success. The move aligns with broader industry trends toward pediatric-specific diabetes therapies.
What we're watching
- Market Penetration
- How quickly MannKind can secure insurance coverage and formulary access for Afrezza in the pediatric population.
- Competitive Response
- Whether rivals like Novo Nordisk or Eli Lilly will accelerate pediatric diabetes drug development.
- Commercial Execution
- The pace at which MannKind can educate pediatric endocrinologists and diabetes specialists about Afrezza’s new indication.
Related topics